Therapeutic-induced hypertension in patients with noncardioembolic acute stroke

被引:46
|
作者
Bang, Oh Young [1 ]
Chung, Jong-Won [1 ]
Kim, Soo-Kyoung [2 ,3 ]
Kim, Suk Jae [4 ]
Lee, Mi Ji [1 ]
Hwang, Jaechun [5 ]
Seo, Woo-Keun [1 ]
Ha, Yeon Soo [6 ]
Sung, Sang Min [7 ]
Kim, Eung-Gyu [8 ]
Sohn, Sung-Il [9 ]
Han, Moon-Ku [10 ]
机构
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Neurol, Seoul, South Korea
[2] Gyeongsang Natl Univ, Coll Med, Dept Neurol, Jinju, South Korea
[3] Gyeongsang Natl Univ, Coll Med, Inst Hlth Sci, Jinju, South Korea
[4] Hana Gen Hosp, Dept Neurol, Cheongju, South Korea
[5] Kyungpook Natl Univ, Chilgok Hosp, Dept Neurol, Daegu, South Korea
[6] Wonkwang Univ, Sch Med, Dept Neurol, Iksan, South Korea
[7] Pusan Natl Univ Hosp, Dept Neurol, Busan, South Korea
[8] Inje Univ, Busan Paik Hosp, Dept Neurol, Gimhae, South Korea
[9] Keimyung Univ, Sch Med, Dept Neurol, Daegu, South Korea
[10] Seoul Natl Univ, Bundang Hosp, Dept Neurol, Seongnam, South Korea
关键词
ACUTE ISCHEMIC-STROKE; HEALTH-CARE PROFESSIONALS; BLOOD-PRESSURE; EARLY MANAGEMENT; SCIENTIFIC STATEMENT; CEREBRAL-ARTERIES; GUIDELINES; COUNCIL; CIRCULATION; ANGIOGRAPHY;
D O I
10.1212/WNL.0000000000008520
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective To evaluate the safety and efficacy of induced hypertension in patients with acute ischemic stroke. Methods In this multicenter randomized clinical trial, patients with acute noncardioembolic ischemic stroke within 24 hours of onset who were ineligible for revascularization therapy and those with progressive stroke during hospitalization were randomly assigned (1:1) to the control and intervention groups. In the intervention group, phenylephrine was administered intravenously to increase systolic blood pressure (SBP) up to 200 mm Hg. The primary efficacy endpoint was early neurologic improvement (reduction in NIH Stroke Scale [NIHSS] score of >= 2 points during the first 7 days). The secondary efficacy endpoint was a modified Rankin Scale score of 0 to 2 at 90 days. Safety outcomes included symptomatic intracranial hemorrhage/edema, myocardial infarction, and death. Results In the modified intention-to-treat analyses, 76 and 77 patients were included in the intervention and control groups, respectively. After adjustment for age and initial stroke severity, induced hypertension increased the occurrence of the primary (odds ratio 2.49, 95% confidence interval [CI] 1.25-4.96, p = 0.010) and secondary (odds ratio 2.97, 95% CI 1.32-6.68, p = 0.009) efficacy endpoints. Sixty-seven (88.2%) patients of the intervention group exhibited improvements in NIHSS scores of >= 2 points during induced hypertension (mean SBP 179.7 +/- 19.1 mm Hg). Safety outcomes did not significantly differ between groups. Conclusion Among patients with noncardioembolic stroke who were ineligible for revascularization therapy and those with progressive stroke, phenylephrine-induced hypertension was safe and resulted in early neurologic improvement and long-term functional independence. ClinicalTrials.gov identifier NCT01600235. Classification of evidence This study provides Class III evidence that for patients with acute ischemic stroke, therapeutic-induced hypertension increases the probability of early neurologic improvement.
引用
收藏
页码:E1955 / E1963
页数:9
相关论文
共 50 条
  • [1] Spontaneous and Therapeutic-Induced Mechanisms of Functional Recovery After Stroke
    Cassidy, Jessica M.
    Cramer, Steven C.
    TRANSLATIONAL STROKE RESEARCH, 2017, 8 (01) : 33 - 46
  • [2] Spontaneous and Therapeutic-Induced Mechanisms of Functional Recovery After Stroke
    Jessica M. Cassidy
    Steven C. Cramer
    Translational Stroke Research, 2017, 8 : 33 - 46
  • [3] Retrospective Analysis of Argatroban in 353 Patients with Acute Noncardioembolic Stroke
    Oguro, Hiroaki
    Mitaki, Shingo
    Takayoshi, Hiroyuki
    Abe, Satoshi
    Onoda, Keiichi
    Yamaguchi, Shuhei
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2018, 27 (08): : 2175 - 2181
  • [4] Therapeutic-induced immunosuppression: knowledge improvment
    Lagrange, PH
    Herrmann, JL
    Wargnier, A
    NEPHROLOGIE, 2002, 23 (03): : 111 - 112
  • [5] Dabigatran Treatment of Acute Noncardioembolic Ischemic Stroke
    Butcher, Ken S.
    Ng, Kelvin
    Sheridan, Patrick
    Field, Thalia S.
    Coutts, Shelagh B.
    Siddiqui, Muzzafar
    Gioia, Laura C.
    Buck, Brian
    Hill, Michael D.
    Miller, Jodi
    Klahr, Ana C.
    Sivakumar, Leka
    Benavente, Oscar R.
    Hart, Robert G.
    Sharma, Mike
    STROKE, 2020, 51 (04) : 1190 - 1198
  • [6] Therapeutic Challenges in Patients With Noncardioembolic Acute Ischemic Stroke in Need of Double Antiplatelet Therapy for Coronary Artery Disease
    Darabont, Roxana Oana
    Stoicescu, Claudiu
    Tiu, Cristina
    AMERICAN JOURNAL OF THERAPEUTICS, 2019, 26 (02) : E213 - E221
  • [7] Pharmacologically Induced Hypertension Therapy for Acute Stroke Patients
    Lee, Min Hwan
    Kim, Joong-Goo
    Jeon, Sang Bum
    Kang, Dong-Wha
    Kwon, Sun U.
    Kim, Jong S.
    JOURNAL OF STROKE, 2019, 21 (02) : 228 - 230
  • [8] Noncardioembolic Stroke in Patients with Atrial Fibrillation
    Katsi, Vasiliki
    Georgiopoulos, Georgios
    Skafida, Anastasia
    Oikonomou, Dimitrios
    Klettas, Dimitrios
    Vemmos, Konstantinos
    Tousoulis, Dimitris
    ANGIOLOGY, 2019, 70 (04) : 299 - 304
  • [9] Safety of induced hypertension therapy in acute ischemic stroke patients
    Koenig, MA
    Geocadin, RG
    de Grouchy, M
    Vimal, S
    Glasgow, J
    Restrepo, L
    Wityk, RJ
    NEUROLOGY, 2005, 64 (06) : A307 - A308
  • [10] Safety of induced hypertension therapy in patients with acute ischemic stroke
    Matthew A. Koenig
    Romergryko G. Geocadin
    Megan de Grouchy
    James Glasgow
    Sangeetha Vimal
    Lucas Restrepo
    Robert J. Wityk
    Neurocritical Care, 2006, 4 : 3 - 7